Clofarabine
- Generic Name
- Clofarabine
- Brand Names
- Clolar, Evoltra
- Drug Type
- Small Molecule
- Chemical Formula
- C10H11ClFN5O3
- CAS Number
- 123318-82-1
- Unique Ingredient Identifier
- 762RDY0Y2H
- Background
Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaemia (ALL), only after at least two other ...
- Indication
For the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphocytic (lymphoblastic) leukemia after at least two prior regimens. It is designated as an orphan drug by the FDA for this use.
- Associated Conditions
- Refractory Acute Lymphoblastic Leukemia (ALL), Refractory Acute Myeloid Leukemia (AML), Relapsed Acute Lymphoblastic Leukemia (ALL), Refractory Langerhans cell histiocytosis
- Associated Therapies
- -
Treatment of Older Adults With Acute Lymphoblastic Leukemia
- First Posted Date
- 2009-09-09
- Last Posted Date
- 2017-03-30
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT00973752
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
S0910 Epratuzumab, Cytarabine, and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2009-07-24
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 35
- Registration Number
- NCT00945815
- Locations
- 🇺🇸
Wayne Hospital, Greenville, Ohio, United States
🇺🇸Glacier Oncology, PLLC, Kalispell, Montana, United States
🇺🇸Charles F. Kettering Memorial Hospital, Kettering, Ohio, United States
Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2009-07-22
- Last Posted Date
- 2014-02-27
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 82
- Registration Number
- NCT00943592
- Locations
- 🇺🇸
The University of Chicago, Chicago, Illinois, United States
T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML)
- Conditions
- Interventions
- First Posted Date
- 2009-07-15
- Last Posted Date
- 2020-02-19
- Target Recruit Count
- 6
- Registration Number
- NCT00939653
- Locations
- 🇺🇸
University of Miami Cancer Center, Miami, Florida, United States
🇺🇸Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Children's Memorial, Chicago, Illinois, United States
A Phase II, Open-Label Study of Clofarabine in Paediatric Patients With Refractory/Relapsed Acute Lymphoblastic Leukaemia
- Conditions
- First Posted Date
- 2009-06-30
- Last Posted Date
- 2014-02-11
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 74
- Registration Number
- NCT00930098
A Study of Clofarabine in Older Patients With Acute Myeloid Leukemia (AML) for Whom Chemotherapy Is Not Suitable
- First Posted Date
- 2009-06-19
- Last Posted Date
- 2015-04-01
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 69
- Registration Number
- NCT00924443
Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies
- First Posted Date
- 2009-05-25
- Last Posted Date
- 2018-01-12
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 44
- Registration Number
- NCT00908167
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS)
- First Posted Date
- 2009-05-18
- Last Posted Date
- 2018-11-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 42
- Registration Number
- NCT00903760
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Clofarabine, Etoposide, and Mitoxantrone for Relapsed and Refractory Acute Leukemias
- First Posted Date
- 2009-04-16
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- Milton S. Hershey Medical Center
- Target Recruit Count
- 22
- Registration Number
- NCT00882076
- Locations
- 🇺🇸
Penn State Hershey Cancer Institute, Hershey, Pennsylvania, United States
Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual Disease
- Conditions
- Adult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Recurrent Adult Acute Myeloid LeukemiaAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
- Interventions
- First Posted Date
- 2009-03-18
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 2
- Registration Number
- NCT00863434
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.